Atonco today announces that Adrien Reymond, PharmD, B.Eng and EMBA candidate, will lead regulatory affairs and quality.
Adrien brings 15 years of experience in the radiopharmaceutical industry, including at AAA (a Novartis company), PETNET Solutions (a Siemens company), Atlanpole Biotherapies, and as a consultant for innovative radiopharmaceutical companies. He will be responsible for pharmaceutical, regulatory, and quality assurance affairs, ensuring compliance with Good Clinical Practices (GCP) and overseeing preparation for ISO 9001:2015 certification.
The entire Atonco team is delighted to welcome Adrien Reymond to the company, both for his expertise and experience in the radiopharmaceutical industry and for his enthusiasm in joining the Atonco adventure.
About ATONCO
ATONCO is a French private company developing molecularly targeted radiopharmaceutical products for oncological applications. Originating from the world-class nuclear medicine centre in Nantes, ATONCO and its partners are committed to the clinical use of alpha-emitting radionuclides, particularly astatine-211 (²¹¹At).
For more information, visit www.atonco-pharma.com